drug delivery

News

Halozyme has expanded its portfolio of drug delivery technologies for a second time in a few months with the acquisition of Surf Bio for up to $400m.

News

Sanofi is reported to be preparing a move to take control of US biotech Ocular Therapeutix, after an initial bid was rejected last year.

R&D

Delivery innovations don’t just improve outcomes – they reshape the entire therapy ecosystem.

News

MSD's Keytruda will soon be available as a subcutaneous injection, improving convenience for patients and defending it from a looming patent loss.

News

Biogen buys Alcyone, bringing a partnered technology for delivery of antisense drugs into the central nervous system in-house.

News

Before it has even launched, Eisai has filed to widen subcutaneous Leqembi's label to include starting as well as maintenance dosing in Alzheimer's.